MRNA
Moderna, Inc.
69.86
-
2.13
2.96%
3 x 69.82
5 x 69.89
bid
ask
4 @ 04:00 PM
70.06+0.20 (0.29%)
Bearish
297
Bullish
580
sentiment
69.82
day range
73.35
62.55
52 week range
170.47
Prev Close71.99
Open72.33
Low69.82
High73.35
Volume4.25M
Avg. Volume4.39M
Market Cap26.85B
Inst. Own72.72%
Beta1.67
Short Ratio5.61
Div & Yield0.00 /
EPS-15.35
P/E0.00
1yr Target91.85
50day MA94.01
200day MA106.08
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split
...
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
This topic has been deleted. Only users with topic management privileges can see it.
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more (NYSE:OXM)
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •